Novartis Scemblix® shows superior major molecular response

MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Switzerland ,America ,Michael Meo ,Zain Iqbal ,Richard Jarvis ,Satoshi Sugimoto ,Parag Mahanti ,Jonathan Graham ,Imke Kappes ,Isabella Zinck ,Sloan Simpson ,Marlena Abdinoor ,Julie Masow ,Novartis Scemblix ,Shreeram Aradhye ,Samir Shah ,Tim Hughes ,Nicole Zinsli Somm ,Novartis ,Dmax Foundation ,Facebook ,Exchange Commission ,Australian Health Medical Research Institute ,Instagram ,Linkedin ,Leukemia Research ,South Australian Health ,Medical Research Institute ,Chief Medical Officer ,Novartis Commitment ,Term Outcomes ,Imatinib Treatment ,Chronic Myeloid ,Year Study Results ,Dasatinib Versus Imatinib Study ,Chronic Myeloid Leukemia Patients ,Chronic Myeloid Leukemia ,Clin Adv Hematol ,Versus Imatinib ,Newly Diagnosed Chronic Myeloid Leukemia ,Results From ,Product Characteristics ,Randomized Study ,Provides Durable Molecular Response ,Primary Efficacy ,Safety Results ,Allosteric Inhibitor ,Tyrosine Kinase Activity ,Des Devel ,Reveals Significant ,Durable Responses ,Chronic Phase ,Exhibits Safety ,Phasei Study ,Asciminib Plus Nilotinib ,Therapy Using Asciminib Plus Imatinib ,Previously Treated With ,Adult Patients With Newly Diagnosed ,More Tyrosine Kinase ,Patients With ,Treatment Optimization ,Swiss Stock Exchange Novn ,Novartis Pharma Ag ,Media Release ,D Hoc ,Reimagine Medicine ,Ncology ,Medical Innovations ,